Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
AFP2d
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. Its first approved indication could come as early ...
The Motley Fool4d
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The biotech has many more tricks up its sleeves. It recently earned approval for its next-gen cystic fibrosis (CF) therapy, Alyftrek. Vertex has a monopoly in the CF drug market. Alyftrek is yet ...
pharmaphorum4d
FDA approves flurry of drugs ahead of holiday season
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the SKYLINE 102 and SKYLINE 103 trials, which showed that Alyftrek matched ...
Nasdaq5d
The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics
Vertex is preparing for two potential near-term launches — suzetrigine in acute pain and vanza triple in CF in 2025. Vanza triple was approved as Alyftrek in December. It is rapidly progressing ...
LinkedIn4d
Computer Bob Emmelkamp’s Post
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis https://lnkd.in/gAEHw-XJ ...